Prevalence of Actionable Drug-Gene Interactions among Patients with Cardiovascular Diseases: A Cross-Sectional Study in the PharmLines Initiative

Pharmacogenetic variants influence individual responses to medications. This study uses PharmLines (2019-2024) to estimate the prevalence of actionable drug-gene interactions in patients using CVD-related medications (≥ 2 prescriptions of the same CVD drug within 180 days). It also examines downstream benefits of PGx testing, where testing results guide not only initial therapy but may also benefit subsequent medications associated with the same gene. Quantifying these benefits can fill gaps in health economic evaluations and provide evidence to support the broader implementation of PGx testing for optimizing treatment and improving outcomes in CVD care.